Profile data is unavailable for this security.
About the company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
- Revenue in USD (TTM)5.50m
- Net income in USD-125.13m
- Incorporated2002
- Employees117.00
- LocationDbv Technologies SABatiment IRO, 107 Av. de la RepubliqueCHATILLON 92320FranceFRA
- Phone+33 155427878
- Fax+33 143261083
- Websitehttps://www.dbv-technologies.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 338.99m | 28.55m | 732.05m | 253.00 | 32.04 | -- | 24.04 | 2.16 | 0.1404 | 0.1404 | 2.00 | -1.62 | 0.863 | -- | 3.45 | 1,339,870.00 | 7.27 | -6.08 | 11.57 | -7.13 | -- | -- | 8.42 | -11.01 | -- | 4.73 | 1.82 | -- | -20.63 | -3.89 | 100.09 | -56.87 | -54.38 | -- |
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 785.60m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 819.99m | 304.00 | -- | -- | -- | 2.70 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Pacira Biosciences Inc | 716.79m | 21.44m | 894.75m | 790.00 | 46.68 | 1.29 | 7.96 | 1.25 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Phathom Pharmaceuticals Inc | 147.19m | -274.55m | 936.58m | 427.00 | -- | -- | -- | 6.36 | -3.81 | -3.81 | 2.04 | -5.95 | 0.4693 | 5.58 | 3.83 | 344,707.30 | -87.53 | -72.89 | -117.10 | -84.11 | 87.25 | -- | -186.53 | -1,799.61 | 2.19 | -3.35 | 3.68 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 989.63m | 97.00 | 34.71 | 4.25 | 31.93 | 12.32 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.07bn | 165.00 | -- | 4.50 | -- | 25.30 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 1.13bn | 394.00 | -- | -- | -- | 4.25 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Day One Biopharmaceuticals Inc | 133.67m | -151.76m | 1.17bn | 184.00 | -- | 2.58 | -- | 8.72 | -1.48 | -1.48 | 1.30 | 4.39 | 0.2399 | 2.88 | 10.53 | 738,519.30 | -27.23 | -39.78 | -29.80 | -43.02 | 89.44 | -- | -113.53 | -414.14 | 8.55 | -- | 0.00 | -- | -- | -- | 49.45 | -- | -- | -- |
| DBV Technologies SA - ADR | 5.50m | -125.13m | 1.21bn | 117.00 | -- | 10.82 | -- | 219.04 | -5.25 | -5.25 | 0.2325 | 1.93 | 0.0541 | -- | 0.3051 | 50,953.70 | -122.95 | -53.12 | -203.22 | -65.60 | -- | -- | -2,273.91 | -1,295.42 | -- | -- | 0.00 | -- | -73.61 | -22.35 | -56.64 | -- | -16.02 | -- |
| Amphastar Pharmaceuticals Inc | 723.31m | 111.63m | 1.31bn | 2.03k | 12.64 | 1.70 | 7.82 | 1.81 | 2.26 | 2.26 | 14.69 | 16.76 | 0.4505 | 2.32 | 5.05 | 356,659.30 | 6.95 | 9.84 | 7.84 | 11.71 | 49.36 | 49.55 | 15.43 | 17.15 | 2.21 | 8.96 | 0.4397 | 0.00 | 13.59 | 17.82 | 15.98 | 26.66 | -0.2486 | -- |
| Collegium Pharmaceutical Inc | 757.07m | 58.44m | 1.45bn | 357.00 | 28.56 | 5.27 | 5.09 | 1.91 | 1.60 | 1.60 | 19.94 | 8.70 | 0.467 | 8.51 | 3.27 | 2,120,636.00 | 3.60 | 4.11 | 5.02 | 6.64 | 57.22 | 55.50 | 7.72 | 8.48 | 1.27 | 2.23 | 0.7462 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.62bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 379.59m | -29.23m | 1.63bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.70bn | 127.00 | 17.59 | 1.68 | 10.14 | 4.37 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
Data as of Feb 13 2026. Currency figures normalised to Dbv Technologies SA's reporting currency: US Dollar USD
20.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Artisan Partners LPas of 31 Dec 2025 | 3.31m | 8.24% |
| Baker Bros. Advisors LPas of 12 Jan 2026 | 1.46m | 3.64% |
| Octagon Capital Advisors LPas of 30 Sep 2025 | 1.02m | 2.54% |
| Yiheng Capital Management LPas of 30 Sep 2025 | 656.31k | 1.63% |
| Great Point Partners LLCas of 30 Sep 2025 | 378.59k | 0.94% |
| Adage Capital Management LPas of 30 Sep 2025 | 345.93k | 0.86% |
| Millennium Management LLCas of 30 Sep 2025 | 337.86k | 0.84% |
| UBS Securities LLCas of 31 Dec 2025 | 244.86k | 0.61% |
| New York State Common Retirement Fundas of 31 Dec 2025 | 223.19k | 0.56% |
| Atika Capital Management LLCas of 31 Dec 2025 | 206.88k | 0.52% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
